Preliminary pharmacokinetics of a new pyridopyrimidine derivative.
This paper describes the preliminary pharmacokinetic studies of 4-anilino-2-methylthiopyrido[2,3-d]pyrimidine (MD-39-AM) following a single administration of the compound to male rats via different routes (intravenous and oral) in the dose range of 6-24 mg.kg-1. The plasma level versus time plots after intravenous and oral administration to male rats can well be described by an open two-compartment model. The product was rapidly absorbed and peak concentrations in plasma were reached before 1 h after a single oral administration whatever the dose studied. The absolute bioavailability calculated on the basis of AUC0-infinity after intravenous and oral administration was estimated to be about 90%. Plasma levels found at higher doses than 6 mg/kg suggest that the product kinetics is dose dependent.
Department of Research, Laboratories Morrith, Madrid, Spain.
M J
MJ
Pérez
M J
MJ
Roch
M C
MC
Ochoa
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004232:Diuretics / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008297:Male; D011485:Protein Binding; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D011919:Rats, Inbred Strains; D013056:Spectrophotometry, Ultraviolet
D004232:Diuretics; D011743:Pyrimidines; C071161:MD 39-AM